Evidence map›Paper›PMID 30046379›Full record

ArticleOxidative medicine and cellular longevity2018

The Role of Nrf2 Signaling in PPAR

Rosario Jimenez, Marta Toral, Manuel Gómez-Guzmán, Miguel Romero, Manuel Sanchez, Ayman M Mahmoud, Juan Duarte

Open access · hybridAbstract read
In one paragraph

Article in Oxidative medicine and cellular longevity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. A flavonoid-rich fraction ofFrontiers in pharmacology · 2023
    Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. PPARβ/δ Agonist Alleviates Diabetic OsteoporosisFrontiers in cell and developmental biology · 2021
    Article
  16. Article
  17. RSC advances · 2019
    Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 3 countries.

Rosario JimenezDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.ORCID 0000-0003-3872-2669
Marta ToralDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.
Manuel Gómez-GuzmánDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.ORCID 0000-0003-2452-9286
Miguel RomeroDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.
Manuel SanchezDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.
Ayman M MahmoudPhysiology Division, Department of Zoology, Faculty of Science, Beni-Suef University, Beni Suef, Egypt.
Juan DuarteDepartment of Pharmacology, School of Pharmacy, University of Granada, Granada, Spain.
Universidad de Granada · ESBeni-Suef University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperglycemia induces oxidative stress and plays a substantial role in the progression of vascular diseases. Here, we demonstrated the potentiality of peroxisome proliferator-activated receptor (PPAR)

Indexed as

AnimalsDiabetes Mellitus, ExperimentalGlucoseHeme Oxygenase-1HumansHuman Umbilical Vein Endothelial CellsHyperglycemiaMaleNAD(P)H Dehydrogenase (Quinone)NADPH OxidasesNF-E2-Related Factor 2Oxidative StressPPAR-betaPPAR deltaRatsRats, WistarGlucoseHeme Oxygenase-1NAD(P)H Dehydrogenase (Quinone)NADPH OxidasesNF-E2-Related Factor 2NQO1 protein, humanPPAR-betaPPAR deltaReactive Oxygen SpeciesSuperoxides

Identifiers

PMID30046379
PMCPMC6036815
OpenAlexW2810211680

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.